Uncategorized-EN
I Lost My Son and Found My Purpose
We spoke with the founder of the first sarcoma organization in Bulgaria, Lidiya Vitanova, who lost her young son, Niki, to sarcoma. Lidiya talked to us about the sarcoma situation in her country as well as her motivation and goals for improving the outcomes of people diagnosed with sarcoma and other rare diseases.
Read MoreYour poster @CTOS 2023
Show Off Your Advocacy Work at CTOS 2023, to the broadest international community of sarcoma experts: Create and Submit a Poster! Sarcoma patient advocacy organizations are cordially invited to participate in SPAGN’s poster presentation session that will be held at this year’s CTOS conference. This session is an opportunity for you to showcase your organization…
Read MoreCheck It Out!
Sarcoma patient and patient advocate Roger Wilson shares his experience of finding a lump – what happened and what he learned.
Read MorePatient Advocacy @CTOS 2023
It is our great pleasure to announce that patient advocacy will once again have a well-earned place at the Connective Tissue Oncology Society (CTOS) Annual Meeting. We will be hosting the Patient Advocacy Lounge at CTOS 2023 in Dublin: Patient Advocacy Lounge Liffey Hall 2, Convention Centre Dublin Open from Thursday, November 2 –…
Read MoreQuality of life in sarcomas?
Incorporating the patient voice in sarcoma research: How can we assess quality of life of sarcoma patients? Soft tissue and bone sarcoma patients form a diverse and rare patient group. Quality of life questionnaires used in research and clinical practice are not always complete and relevant for the unique experiences of this patient group. Take…
Read MoreTNG462 in MTAP-deleted Solid Tumors including MPNST
Agents: TNG462 Phase I/II Status Recruiting Sponsor Tango Therapeutics Further information on Clinicaltrials.gov. Phase I/II study in solid tumor patients with a specific genetic mutation, a MTAP deletion, including malignant peripheral nerve sheath tumors (MPNST) WHO is the trial for? Patients of 18 years or older Patients must have a diagnosis of…
Read MoreAbemaciclib (LY2835219) in Ewing’s Sarcoma: CAMPFIRE
Trial name: CAMPFIRE: Abemaciclib (LY2835219) in Ewing’s Sarcoma Agents: Abemaciclib (LY2835219) Phase II Status Recruiting Sponsor Eli Lilly and Company This is a Phase II study that aims to measure the benefit of adding abemaciclib to chemotherapy (irinotecan and temozolamide) for Ewing’s sarcoma that has come back or did not respond to treatment.…
Read MoreRead the latest in our SPAGN Newsletter!
The last few months have been filled with activities, from the SPAGN Annual Conference and New Horizons GIST to our surveys and now Sarcoma Awareness Month in July. And there’s more to come. Read on here in our latest newsletter (July 2023) to learn what the SPAGN team has been up to . Want to…
Read MoreWhen the Patient Becomes the Researcher
Dr. Sydney Stern, biomedical scientist and patient advocate, describes her personal journey as a patient with a rare tumor disease and her quest for answers through science. She calls for patients to get involved in research and outlines options for doing so.
Read MoreFacilitating Collaboration in Sarcoma Care
In this interview, SPAGN Communications Director Cory Archibald speaks with Dr. Bernd Kasper, to learn about the role of patient advocacy groups like SPAGN in strengthening global cooperation to improve patient outcomes.
Read More